July 2, 2020 07:08 AM EDTUpdated 09:59 AM

Novartis loses biosimilar appeal as court upholds a 31-year monopoly by Amgen's Enbrel

Amber Tong

A new court ruling has strengthened Amgen’s grip on the IP estate around Enbrel, keeping biosimilars of the autoimmune and inflammatory drug at bay until …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis loses biosimilar appeal as court upholds a 31-year monopoly by Amgen's Enbrel

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Intellia to cut workforce by 27%, plans commercialization of first CRISPR therapy in 2027

Lilly ventures into pulmonary fibrosis with startup Mediar

John Maraganore turns to ex-Alnylam colleague to lead his latest RNAi bet; Amylyx names commercial chief

With $120M, GSK-allied Ouro Medicines throws its hat into burgeoning TCE ring

Another biotech scoops up asset from China-based Keymed and nabs $180M

Repare pauses late-stage plans, reshuffles pipeline in effort to cut costs

No­var­tis los­es biosim­i­lar ap­peal as court up­holds a 31-year mo­nop­oly by Am­gen's En­brel

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Novartis loses biosimilar appeal as court upholds a 31-year monopoly by Amgen's Enbrel